Apyx Medical (NASDAQ:APYX) Issues Quarterly Earnings Results

Key Points

• Apyx reported a quarterly EPS beat of ($0.05) vs. consensus ($0.11) and revenue of $12.49M, up about 32% year-over-year driven by Surgical Aesthetics sales of $10.7M.
• Management says the AYON system is in an early but fast ramp after its Sept 2025 launch and expects FDA 510(k) clearance for power-assisted liposuction this quarter, while raising 2026 revenue guidance to $59M–$60M with targeted gross margins of ~62%–63% and operating expenses capped at $45M.
• Despite progress, Apyx remains unprofitable (Q1 net loss attributable to stockholders $2.1M) with $31.1M cash and a stated runway through 2027, and the stock jumped about 21.9% on the report.

Apyx Medical (NASDAQ:APYX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.06, FiscalAI reports. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%. The firm had revenue of $12.49 million during the quarter, compared to analyst estimates of $10.78 million.

Here are the key takeaways from Apyx Medical's conference call:

• Apyx reported strong top-line growth in Q1 — $12.5M total revenue, up 32% year-over-year, driven by a 36% increase in Surgical Aesthetics sales to $10.7M largely from AYON system and consumable handpiece demand.
• Management says AYON is in an early but fast ramp following its Sept 2025 launch, and expects FDA 510(k) clearance for power-assisted liposuction this quarter with a limited early-adopter commercial rollout planned.
• The company raised 2026 revenue guidance to $59M–$60M, projects gross margins of ~62%–63% and capped operating expenses at $45M, reflecting improved profitability trends (Q1 GAAP net loss narrowed vs. prior year).
• International momentum is building after recent approvals (notably South Korea), with initial generator and handpiece demand exceeding expectations and plans to register AYON in major markets over time.
• Despite improvements, Apyx remains unprofitable (Q1 net loss attributable to stockholders was $2.1M), expects OEM revenue to decline year-over-year, and has a stated cash runway through 2027 with $31.1M in cash as of March 31, 2026.

Apyx Medical Stock Up 21.9%

Shares of NASDAQ:APYX traded up $0.64 during trading on Thursday, reaching $3.56. 761,219 shares of the company traded hands, compared to its average volume of 178,440. The firm has a fifty day simple moving average of $3.63 and a 200 day simple moving average of $3.70. The firm has a market cap of $148.91 million, a P/E ratio of -13.18 and a beta of 1.35. Apyx Medical has a 1-year low of $1.08 and a 1-year high of $4.50. The company has a quick ratio of 4.26, a current ratio of 5.00 and a debt-to-equity ratio of 2.35.

Institutional Investors Weigh In On Apyx Medical

A number of institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC boosted its stake in shares of Apyx Medical by 19.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company's stock valued at $13,909,000 after buying an additional 636,043 shares during the period. Vanguard Group Inc. boosted its stake in shares of Apyx Medical by 3.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company's stock valued at $3,272,000 after buying an additional 53,175 shares during the period. Geode Capital Management LLC boosted its stake in shares of Apyx Medical by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 358,829 shares of the company's stock valued at $1,257,000 after buying an additional 7,551 shares during the period. Informed Momentum Co LLC acquired a new stake in shares of Apyx Medical during the 4th quarter valued at $863,000. Finally, 683 Capital Management LLC acquired a new stake in shares of Apyx Medical during the 4th quarter valued at $436,000. Institutional investors and hedge funds own 55.33% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wall Street Zen lowered shares of Apyx Medical from a "buy" rating to a "hold" rating in a research note on Sunday, April 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Apyx Medical in a report on Friday, March 27th. Craig Hallum upped their target price on Apyx Medical from $5.00 to $6.00 and gave the company a "buy" rating in a report on Wednesday, March 11th. Finally, BTIG Research upgraded Apyx Medical from a "neutral" rating to a "buy" rating and set a $6.00 target price on the stock in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $6.50.

About Apyx Medical

Apyx Medical NASDAQ: APYX is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.